Free Trial
NASDAQ:GUTS

Fractyl Health (GUTS) Stock Price, News & Analysis

Fractyl Health logo
$1.12 -0.04 (-3.45%)
As of 11:14 AM Eastern

About Fractyl Health Stock (NASDAQ:GUTS)

Key Stats

Today's Range
$1.10
$1.20
50-Day Range
$1.11
$2.09
52-Week Range
$1.10
$7.89
Volume
103,203 shs
Average Volume
288,368 shs
Market Capitalization
$54.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Remove Ads

Fractyl Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

GUTS MarketRank™: 

Fractyl Health scored higher than 29% of companies evaluated by MarketBeat, and ranked 802nd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fractyl Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fractyl Health has only been the subject of 1 research reports in the past 90 days.

  • Read more about Fractyl Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Fractyl Health are expected to decrease in the coming year, from ($1.61) to ($1.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fractyl Health is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fractyl Health is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Fractyl Health's valuation and earnings.
  • Percentage of Shares Shorted

    14.48% of the float of Fractyl Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Fractyl Health has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Fractyl Health has recently decreased by 0.33%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fractyl Health does not currently pay a dividend.

  • Dividend Growth

    Fractyl Health does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.48% of the float of Fractyl Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Fractyl Health has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Fractyl Health has recently decreased by 0.33%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Fractyl Health this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for GUTS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fractyl Health insiders have sold 913.70% more of their company's stock than they have bought. Specifically, they have bought $20,323.00 in company stock and sold $206,015.00 in company stock.

  • Read more about Fractyl Health's insider trading history.
Receive GUTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fractyl Health and its competitors with MarketBeat's FREE daily newsletter.

GUTS Stock News Headlines

Fractyl Health reports early data from REVEAL-1 cohort of REMAIN-1 study
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025
See More Headlines

GUTS Stock Analysis - Frequently Asked Questions

Fractyl Health's stock was trading at $2.06 on January 1st, 2025. Since then, GUTS shares have decreased by 45.6% and is now trading at $1.12.
View the best growth stocks for 2025 here
.

Fractyl Health, Inc. (NASDAQ:GUTS) announced its earnings results on Monday, March, 3rd. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.08.

Fractyl Health (GUTS) raised $110 million in an IPO on Friday, February 2nd 2024. The company issued 7,333,333 shares at a price of $15.00 per share.

Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fractyl Health investors own include SoFi Technologies (SOFI), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
3/03/2025
Today
4/03/2025
Next Earnings (Estimated)
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:GUTS
Previous Symbol
NASDAQ:GUTS
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+762.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-77,090,000.00
Net Margins
-64,849.48%
Pretax Margin
-64,849.48%

Debt

Sales & Book Value

Annual Sales
$93,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$56.75 million
Optionable
N/A
Beta
0.30
10 Stocks Set to Soar in Spring 2025 Cover

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

This page (NASDAQ:GUTS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners